Status:
COMPLETED
Positron Emission Tomography Study Using 2-[18F]-F-A85380 to Determine α4β2 Neuronal Nicotinic Receptor Occupancy of AZD3480 After Oral Administration to Healthy Male Subjects
Lead Sponsor:
AstraZeneca
Conditions:
Healthy
Eligibility:
MALE
20-80 years
Phase:
PHASE1
Brief Summary
The study is being performed in order to learn more about AZD3480 (potential as treatment for patients with Alzheimer's Disease) and to investigate how much of AZD3480 is bound to the nicotinic recept...
Eligibility Criteria
Inclusion
- Physically Healthy volunteers
- Genotyped with regard to CYP2D6
- Normal MRI scan at Visit 2
Exclusion
- Known or suspected drug or alcohol abuse or positive drugs of abuse screen as judged by the investigator.
- Participation in a PET examination as part of a scientific study during the past twelve months.
- Prescribed or non-prescribed from two weeks prior to the first PET examination. Occasional paracetamol and nasal spray for congestion will be allowed as medication.
Key Trial Info
Start Date :
January 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2008
Estimated Enrollment :
9 Patients enrolled
Trial Details
Trial ID
NCT00686413
Start Date
January 1 2008
End Date
August 1 2008
Last Update
December 10 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Stockholm, Sweden